

Special Issue

Current Status and Clinical Developments in Lung Cancer: What to Expect from Emerging Drugs?

Message from the Guest Editor

Lung cancer, small cell lung cancer and non-small cell lung cancer are the leading causes of cancer-related death. Most of the time, the symptoms appear late; thus, the diagnosis of lung cancer patients occurs at an advanced stage. The treatment of patients with lung cancer includes multidisciplinary approaches that are based on surgical practice, such as chemotherapy, radiotherapy, targeted therapies, and immunotherapy, which largely improve the quality of life and survival rates. For this reason, this Special Issue will embrace innovative treatments, as well as immunotherapy drugs and molecular targeted therapies, that simplify the comprehension of the molecular biology of lung cancer in the era of personalized medicine, with the aid of diagnostic and therapeutic technologies and rational drug design.

Guest Editor

Dr. Federico Pio Fabrizio

Laboratory of Oncology, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy

Deadline for manuscript submissions

closed (15 March 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/164309

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)